Opioid Use Disorder MarketSize and Trends
Global opioid use disorder market is estimated to be valued at US$ 3.24 Bn in 2023, and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).
Figure 1. Global Opioid Use Disorder Market Share (%), By Drug Type, 2023
![](/images/research-%20methodology/758999opioid-use-disorder-market-figure-1.png)
Figure 2. Global Opioid Use Disorder Market Share(%), By Region, 2023
![](/images/research-%20methodology/772680opioid-use-disorder-market-figure-2.png)
Global Opioid Use Disorder Market- Segmentation
Global opioid use disorder market is segmented into drug type, route of administration, distribution channel, and region.
- By drug type, the market is segmented into buprenorphine, methadone, naltrexone, and others. Out of which, buprenorphine segment is expected to hold a dominant position in the global opioid use disorder market during the forecast period due to increasing inorganic growth strategies such as partnership.
- By route of administration, the market is segmented into oral and parenteral. Out of which, parenteral segment is expected to hold a dominant position in the global opioid use disorder market during the forecast period due to increasing use of parenteral drug for the treatment of opioid disorders.
- By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period due to increasing use of catheters in hospitals.
- By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, North America is expected to dominate the market over the forecast period due to increasing organic growth strategies such as product launches and approvals.
Among all the segmentation, the drug type segment is expected to dominate the market over the forecast period due to increasing organic growth strategies such as product launch by key market players to expand their product portfolio. For instance, in May 2020, Hikma Pharmaceuticals PLC., the multinational generic pharmaceutical company, launched buprenorphine hydrochloride injection, 0.3mg/mL, the generic version of buprenex [1] in the U.S. through its U.S. affiliate, Hikma Pharmaceuticals U.S.A.Inc.
Global Opioid Use Disorder Market: Trends
- Increasing inorganic growth strategies such as acquisition: Increasing inorganic growth strategies such as acquisition by key market players to streghten their market presence is expected to drive the global opiod use disorder market growth over the forecast period. For instance, in April 2021, Amneal Pharmaceuticals, Inc., a pharmaceutical company, and Kashiv BioSciences LLC., a pharmaceutical company, announced that Amneal Pharmaceuticals LLC., a pharmaceutical company, had completed its previously announced acquisition of Kashiv Specialty Pharmaceuticals, LLC., a wholly-owned subsidiary of Kashiv that focuses on the development of complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs.